[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614794":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":37,"collaborators":26,"id":39,"slug":26,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":26,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":26,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":26,"overallStatus":58,"whyStopped":26,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":26},{"fullName":5,"class":6},"Eye & ENT Hospital of Fudan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nicotinamide Riboside (NR) Group","EXPERIMENTAL","Participants randomized to this arm will receive a single oral dose of 600 mg NR approximately one hour before their second overnight PSG assessment.",[13],"Dietary Supplement: Nicotinamide Riboside (NR)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Group","PLACEBO_COMPARATOR","Participants randomized to this arm will receive a matching placebo capsule approximately one hour before their second overnight PSG assessment. The placebo is identical in appearance to the NR capsule and contains inert ingredients without active pharmacological effects.",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Nicotinamide Riboside (NR)","A single oral dose of 600 mg NR, an NAD+ precursor compound, provided in capsule form. The dose and timing are standardized for all participants.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","The placebo capsule is visually identical to the NR capsule but contains inert excipients without active pharmacological components.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Shan Sun","CONTACT","+86-021-64377134-2033","sunshine7896@126.com",{"type":38,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100614794",false,"NCT07284225","Acute Effects of Nicotinamide Riboside on Polysomnography-Measured Sleep Structure in Healthy Adults","A Randomized Controlled Study on the Acute Effects of a Single Dose of Nicotinamide Riboside on Sleep Structure in Healthy Adults","Inclusion Criteria:\n\n* Healthy males or females aged 18 to 60 years inclusive;\n* Screening using the Pittsburgh Sleep Quality Index (PSQI) scale with a total score between 5 and 10, indicating mild subjective sleep disturbance;\n* Voluntarily participate in this study and sign a written informed consent form;\n* Able to understand the study procedures and willing to comply with all laboratory regulations.\n\nExclusion Criteria:\n\n* History of any serious neurological, cardiovascular, respiratory, hepatic, renal, hematological, or psychiatric disorders;\n* Medically diagnosed sleep disorders (e.g., insomnia, sleep apnea syndrome, restless legs syndrome);\n* Regular use within the past month of any medication or supplement that may affect sleep (e.g., sedatives, antidepressants, antihistamines, melatonin);\n* Known allergy to nicotinamide riboside (NR) or any component of the study product;\n* History of chronic smoking, heavy alcohol consumption (exceeding weekly recommended intake), or substance abuse;\n* Participation in any other interventional clinical studies within one month prior to study initiation, or exposure to circadian rhythm-disrupting factors such as trans-time zone travel or frequent night shifts;\n* Pregnant women, breastfeeding women, or men of reproductive age with plans to conceive within the next month who are not using effective contraception.",true,"ALL","18 Years","60 Years",{"count":50,"type":51},20,"ESTIMATED","INTERVENTIONAL",[54],"NA","This study aims to evaluate whether a single oral dose of nicotinamide riboside (NR), a precursor of nicotinamide adenine dinucleotide (NAD+), has acute effects on sleep in healthy adults who report mild sleep difficulties. NR is widely used as a nutritional supplement and is known to increase cellular NAD+ levels, which may influence physiological processes linked to sleep-wake regulation.\n\nIn this randomized, double-blind, placebo-controlled study, 20 healthy adults will complete two overnight sleep assessments using polysomnography (PSG), the gold-standard sleep monitoring method. After a baseline night of sleep recording, participants will receive either NR or a placebo before bedtime on the second night. Researchers will compare sleep duration and sleep structure before and after the intervention to determine whether NR has an acute effect on objective sleep quality.\n\nThe study will also evaluate safety and collect participants' subjective sleep impressions. Findings may help clarify whether NR, a widely used nutritional supplement, has measurable short-term effects on human sleep.",[57],"Healthy Volunteers","NOT_YET_RECRUITING","2025-12-14",{"date":61,"type":62},"2025-12-16","ACTUAL",{"date":64,"type":51},"2025-12-20",{"date":66,"type":51},"2026-12-30",{"name":5,"class":6}]